Selected Publications

Academic Article

Year Title Altmetric
2019 Apolipoprotein A-I mimetics mitigate intestinal inflammation in a COX2-dependent inflammatory disease modelJournal of Clinical Investigation.  129:3670-3685. 2019
2019 Corrigendum to “Solid-state NMR structural investigations of peptide-based nanodiscs and of transmembrane helices in bicellar arrangements” [Chem. Phys. Lipids 219 (2019) 58–71] (Chemistry and Physics of Lipids (2019) 219 (58–71), (S0009308418302056), (10.1016/j.chemphyslip.2019.01.012))Chemistry and Physics of Lipids.  221:219. 2019
2019 Lipoprotein modulation of proteinuric renal injuryLaboratory Investigation.  99:1107-1116. 2019
2019 Apolipoprotein A1 Forms 5/5 and 5/4 Antiparallel Dimers in Human High-density LipoproteinMolecular and Cellular Proteomics.  18:854-864. 2019
2019 High-resolution structural studies elucidate antiatherogenic and anti-inflammatory properties of peptides designed to mimic amphipathic α-helical domains of apolipoprotein A-INatural Product Communications.  14. 2019
2019 Solid-state NMR structural investigations of peptide-based nanodiscs and of transmembrane helices in bicellar arrangementsChemistry and Physics of Lipids.  219:58-71. 2019
2019 The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damageChemistry and Physics of Lipids.  219:28-35. 2019
2019 Probing membrane enhanced protein-protein interactions in a minimal redox complex of cytochrome-P450 and P450-reductaseChemical Communications.  55:5777-5780. 2019
2018 Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaquesJournal of Lipid Research.  59:2075-2083. 2018
2018 Nanodisc-Forming Scaffold Protein Promoted Retardation of Amyloid-Beta AggregationJournal of Molecular Biology.  430:4230-4244. 2018
2018 Supramolecular Organization of Apolipoprotein-A-I-Derived Peptides within Disc-like ArrangementsBiophysical Journal.  115:467-477. 2018
2018 Retraction: Crystal structure of human apolipoprotein a-i: Insights into its protective effect against cardiovascular diseases (Proc Natl Acad Sci USA (2006) 103 (2126–2131) DOI: 10.1073/pnas.0506877103)Proceedings of the National Academy of Sciences.  115:E6966. 2018
2018 A Minimal Functional Complex of Cytochrome P450 and FBD of Cytochrome P450 Reductase in NanodiscsAngewandte Chemie.  57:8458-8462. 2018
2018 Real-Time Monitoring of Lipid Exchange via Fusion of Peptide Based Lipid-NanodiscsChemistry of Materials.  30:3204-3207. 2018
2018 Cytochrome-P450-Induced Ordering of Microsomal Membranes Modulates Affinity for DrugsAngewandte Chemie.  57:3391-3395. 2018
2018 ApoA-I Mimetic Peptide 4F Reduces Age-Related Lipid Deposition in Murine Bruch’s Membrane and Causes Its Structural RemodelingCurrent Eye Research.  43:135-146. 2018
2018 Lipid-exchange in nanodiscs discloses membrane boundaries of cytochrome-P450 reductaseChemical Communications.  54:6336-6339. 2018
2018 The apolipoprotein e mimetic peptide AEM-2 attenuates mitochondrial injury and apoptosis in human THP-1 macrophagesCurrent topics in peptide & protein research.  19:15-25. 2018
2017 Kinetic and Structural Characterization of the Effects of Membrane on the Complex of Cytochrome b 5 and Cytochrome cScientific Reports.  7. 2017
2017 Cholesterol reduction and macrophage function: Role of paraoxonasesCurrent Opinion in Lipidology.  28:397-402. 2017
2017 Membrane environment drives cytochrome P450's spin transition and its interaction with cytochrome: B 5Chemical Communications.  53:12798-12801. 2017
2016 Apolipoprotein mimetic peptides as modulators of lipoprotein functionProtein and Peptide Letters.  23:1024-1031. 2016
2016 High-density lipoprotein, mitochondrial dysfunction and cell survival mechanismsChemistry and Physics of Lipids.  199:161-169. 2016
2016 Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol effluxJournal of Lipid Research.  57:1175-1193. 2016
2015 Recent developments in modulating atherogenic lipoproteinsCurrent Opinion in Lipidology.  26:369-375. 2015
2015 Efficacy of tomato concentrates in mouse models of dyslipidemia and cancerPharmacology Research and Perspectives.  3. 2015
2015 Bioenergetic programming of macrophages by the apolipoprotein A-I mimetic peptide 4FBiochemical Journal.  467:517-527. 2015
2015 Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosisJournal of Lipid Research.  56:871-887. 2015
2015 Novel method for reducing plasma cholesterol: A ligand replacement therapyFuture Lipidology.  10:83-90. 2015
2014 Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: A reviewJournal of Lipid Research.  55:2007-2021. 2014
2014 Apolipoprotein A-I mimeticsCurrent Opinion in Lipidology.  25:304-308. 2014
2014 Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18AInnate Immunity.  20:867-880. 2014
2014 L-4F Inhibits Lipopolysaccharide-Mediated Activation of Primary Human NeutrophilsInflammation.  37:1401-1412. 2014
2014 Quantification of HDL particle concentration by calibrated ion mobility analysisClinical Chemistry.  60:1393-1401. 2014
2014 Searching for a successful HDL-based treatment strategyBiochimica et Biophysica Acta Molecular and Cell Biology of Lipids.  1841:162-167. 2014
2014 Searching for a successful HDL-based treatment strategy.BBA - Biochimica et Biophysica Acta.  1841:162-167. 2014
2013 Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acidJournal of Lipid Research.  54:3403-3418. 2013
2013 Cationic peptide mR18L with lipid lowering properties inhibits LPS-induced systemic and liver inflammation in ratsBiochemical and Biophysical Research Communications.  436:705-710. 2013
2013 Recent progress in the development of apoA-I and apoE mimetic therapiesFuture Lipidology.  8:265-268. 2013
2013 Anti-Inflammatory Mechanisms of Apolipoprotein A-I Mimetic Peptide in Acute Respiratory Distress Syndrome Secondary to SepsisPLoS ONE.  8. 2013
2013 A novel approach to oral apoA-I mimetic therapyJournal of Lipid Research.  54:995-1010. 2013
2013 Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null miceAtherosclerosis.  227:58-64. 2013
2013 Lipid complex of apolipoprotein A-I mimetic peptide 4F is a novel platform for paraoxonase-1 binding and enhancing its activity and stabilityBiochemical and Biophysical Research Communications.  430:975-980. 2013
2013 In vivo and in vitro effects of an apolipoprotein E mimetic peptide on amyloid-β pathologyJournal of Alzheimer's Disease.  36:335-347. 2013
2012 Regulation of pattern recognition receptors by the apolipoprotein A-I mimetic peptide 4FArteriosclerosis, Thrombosis, and Vascular Biology.  32:2631-2639. 2012
2012 Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null miceAtherosclerosis.  224:326-331. 2012
2012 Preservation of biological function despite oxidative modification of the apolipoprotein A-I mimetic peptide 4FJournal of Lipid Research.  53:1576-1587. 2012
2012 Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptidesJournal of Lipid Research.  53:849-858. 2012
2012 D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSODInternational Journal of Cancer.  130:1071-1081. 2012
2012 D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null miceJournal of Lipid Research.  53:437-445. 2012
2011 HDL Mimetic Peptide Administration Improves Left Ventricular Filling and Cardiac output in Lipopolysaccharide-Treated Rats.Journal of Clinical and Experimental Cardiology.  2. 2011
2011 Apolipoprotein E mimetics and cholesterol-lowering propertiesAmerican Journal of Cardiovascular Drugs.  11:371-381. 2011
2011 Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasmaJournal of Lipid Research.  52:1795-1809. 2011
2011 Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orallyJournal of Lipid Research.  52:1200-1210. 2011
2011 L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathwaysIntegrative Biology.  3:479-489. 2011
2011 Sequence conservation of apolipoprotein A-I affords novel insights into HDL structure-functionJournal of Lipid Research.  52:435-450. 2011
2011 Structure and lipid interactions of an anti-inflammatory and anti-atherogenic 10-residue class G* apolipoprotein J peptide using solution NMRBBA - Biomembranes.  1808:498-507. 2011
2010 ApoE mimetic peptide reduces plasma lipid hydroperoxide content with a concomitant increase in HDL paraoxonase activityAdvances in Experimental Medicine and Biology.  660:1-4. 2010
2010 Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null miceJournal of Lipid Research.  51:3491-3499. 2010
2010 Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effectsAtherosclerosis.  213:449-457. 2010
2010 L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in miceDrug Metabolism Letters.  4:139-148. 2010
2010 Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancerProceedings of the National Academy of Sciences.  107:19997-20002. 2010
2010 The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic ratsJournal of Lipid Research.  51:2695-2705. 2010
2010 Extracorporeal membrane oxygenation causes loss of intestinal epithelial barrier in the newborn pigletPediatric Research.  68:128-133. 2010
2010 Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophagesAmerican Journal of Physiology - Cell Physiology.  298. 2010
2010 Structure and function of HDL mimeticsArteriosclerosis, Thrombosis, and Vascular Biology.  30:164-168. 2010
2010 Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH2Atherosclerosis.  208:134-141. 2010
2010 Extracorporeal membrane oxygenation causes loss of intestinal epithelial barrier in the newborn pigletPediatric Research.  68:128-133. 2010
2010 L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregationArteriosclerosis, Thrombosis, and Vascular Biology.  30:283-289. 2010
2010 Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestineLaboratory Investigation.  90:128-139. 2010
2009 HDL as a biomarker, potential therapeutic target, and therapyDiabetes.  58:2711-2717. 2009
2009 A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acidsJournal of Lipid Research.  50:1538-1547. 2009
2009 Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipidsBBA - Biomembranes.  1788:1967-1975. 2009
2009 Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic ratsAJP - Heart and Circulatory Physiology.  297. 2009
2009 Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's diseaseNeurobiology of Disease.  34:525-534. 2009
2009 The role of dysfunctional HDL in atherosclerosisJournal of Lipid Research.  50. 2009
2009 Apolipoprotein A-I mimetic peptides.Current Atherosclerosis Reports.  11:52-57. 2009
2009 Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).Vascular Disease Prevention.  6:122-130. 2009
2008 Effect of leucine to phenylalanine substitution on the nonpolar face of a class A amphipathic helical peptide on its interaction with lipid: High resolution solution NMR studies of 4F-dimyristoylphosphatidylcholine discoidal complexJournal of Biological Chemistry.  283:34393-34402. 2008
2008 Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-IJournal of Lipid Research.  49:2302-2311. 2008
2008 HDL therapy for cardiovascular diseases: The road to HDL mimeticsCurrent Atherosclerosis Reports.  10:405-412. 2008
2008 Multiple indications for anti-inflammatory apolipoprotein mimetic peptidesCurrent Opinion in Investigational Drugs.  9:1157-1162. 2008
2008 Apo A-1 mimetic peptides as atheroprotective agents in murine modelsCurrent Drug Targets.  9:204-209. 2008
2008 The Effect of Apolipoprotein Mimetic Peptides in Inflammatory Disorders Other Than AtherosclerosisTrends in Cardiovascular Medicine.  18:61-66. 2008
2008 D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western dietJournal of Lipid Research.  49:192-205. 2008
2007 Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbitsJournal of Lipid Research.  48:2344-2353. 2007
2007 High-density lipoprotein: Antioxidant and anti-inflammatory propertiesCurrent Atherosclerosis Reports.  9:244-248. 2007
2007 Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptidesJournal of Lipid Research.  48:1915-1923. 2007
2007 Peptide mimetics of apolipoproteins improve HDL functionJournal of Clinical Lipidology.  1:142-147. 2007
2007 Apolipoprotein A-I Mimetic Peptides and Their Role in Atherosclerosis PreventionPeptide Science -Symposium-.  2006:225-226. 2007
2007 ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayersJournal of Biological Chemistry.  282:1980-1988. 2007
2006 Apolipoprotein A-I mimetic peptides and their role in atherosclerosis preventionNature Clinical Practice Cardiovascular Medicine.  3:540-547. 2006
2006 D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western dietJournal of Lipid Research.  47:2148-2160. 2006
2006 Mechanisms of disease: Proatherogenic HDL - An evolving fieldNature Clinical Practice Endocrinology and Metabolism.  2:504-511. 2006
2006 Atherosclerosis and vascular disease: Effects of peptide mimetics of apolilpoproteinsCurrent Pharmaceutical Biotechnology.  7:235-240. 2006
2006 Potential clinical utility of high-density lipoprotein-mimetic peptidesCurrent Opinion in Lipidology.  17:440-444. 2006
2006 Synthetic peptides: Managing lipid disordersCurrent Opinion in Lipidology.  17:233-237. 2006
2006 Association of a model class A (apolipoprotein) amphipathic α helical peptide with lipid: High resolution NMR studies of peptide-lipid discoidal complexesJournal of Biological Chemistry.  281:6511-6519. 2006
2006 Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseasesProceedings of the National Academy of Sciences.  103:2126-2131. 2006
2006 Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1Journal of Lipid Research.  47:107-114. 2006
2006 Oral amphipathic peptides as therapeutic agentsExpert Opinion on Investigational Drugs.  15:13-21. 2006
2005 An apolipoprotein A-I mimetic works best in the presence of apolipoprotein A-ICirculation Research.  97:1085-1086. 2005
2005 Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null miceCirculation Research.  97:524-532. 2005
2005 An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null miceArteriosclerosis, Thrombosis, and Vascular Biology.  25:1932-1937. 2005
2005 Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptideCirculation Research.  97:236-243. 2005
2005 ApoA-I mimetic peptides as anti-inflammatory agentsCurrent Medicinal Chemistry Immunology Endocrine and Metabolic Agents.  5:335-338. 2005
2005 Apolipoprotein A-I mimetic peptides - ATVB in focusArteriosclerosis, Thrombosis, and Vascular Biology.  25:1325-1331. 2005
2005 D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null miceArteriosclerosis, Thrombosis, and Vascular Biology.  25:1426-1432. 2005
2005 Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in Watanabe heritable hyperlipidemic rabbitsCirculation.  111:3112-3118. 2005
2005 The role of high-density lipoprotein in inflammationTrends in Cardiovascular Medicine.  15:158-161. 2005
2004 Two homologous apolipoprotein AI mimetic peptides: Relationship between membrane interactions and biological activityJournal of Biological Chemistry.  279:51404-51414. 2004
2004 Human apolipoprotein A-I and A-I mimetic peptides: Potential for atherosclerosis reversalCurrent Opinion in Lipidology.  15:645-649. 2004
2004 Influence of ApoA-I structure on the ABCA1-mediated efflux of cellular lipidsJournal of Biological Chemistry.  279:49931-49939. 2004
2004 D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytesCirculation.  110:3252-3258. 2004
2004 Double belt structure of discoidal high density lipoproteins: Molecular basis for size heterogeneityJournal of Molecular Biology.  343:1293-1311. 2004
2004 Antiinflammatory properties of HDLCirculation Research.  95:764-772. 2004
2004 Model class A and class L peptides increase the production of apoA-I-containing lipoproteins in HepG2 cellsJournal of Lipid Research.  45:1919-1928. 2004
2004 The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transportProceedings of the National Academy of Sciences.  101:13032-13037. 2004
2004 Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol effluxJournal of Biological Chemistry.  279:25966-25977. 2004
2004 Aromatic residue position on the nonpolar face of class A amphipathic helical peptides determines biological activityJournal of Biological Chemistry.  279:26509-26517. 2004
2004 An Apolipoprotein AI Mimetic Peptide: Membrane Interactions and the Role of CholesterolBiochemistry.  43:5073-5083. 2004
2004 Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.Circulation.  109:3215-3220. 2004
2003 Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosisCurrent Opinion in Investigational Drugs.  4:1100-1104. 2003
2003 A quantitative analysis of apolipoprotein binding to SR-BI: Multiple binding sites for lipid-free and lipid-associated apolipoproteinsJournal of Lipid Research.  44:1132-1142. 2003
2003 Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic miceAtherosclerosis.  168:229-237. 2003
2002 Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilizationJournal of Lipid Research.  43:1688-1700. 2002
2002 Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptideCirculation.  106:1127-1132. 2002
2002 Sustained-delivery of an apolipoproteinE-peptidomimetic using multivesicular liposomes lowers serum cholesterol levelsJournal of Controlled Release.  79:207-218. 2002
2002 Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterolCirculation.  105:290-292. 2002
2001 Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptideJournal of Lipid Research.  42:1096-1104. 2001
2001 Toward the design of peptide mimics of antiatherogenic apolipoproteins A-I and ECurrent Science.  81:53-65. 2001
2001 Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivoJournal of Lipid Research.  42:959-966. 2001
2001 NMR conformational analysis of cis and trans proline isomers in the neutrophil chemoattractant, N-acetyl-proline-glycine-prolineBiopolymers.  58:548-561. 2001
2001 A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosisJournal of Lipid Research.  42:545-552. 2001
2001 Solution NMR structure of a model class A (apolipoprotein) amphipathic α helical peptidePeptides.  22:567-573. 2001
2001 Structural models of human apolipoprotein A-I: A critical analysis and reviewBiochimica et Biophysica Acta Molecular and Cell Biology of Lipids.  1531:4-46. 2001
2001 Effect of magainin, class L, and class A amphipathic peptides on fatty acid spin labels in lipid bilayersBBA - Biomembranes.  1511:28-41. 2001
2001 Osmotically induced membrane tension modulates membrane permeabilization by class L amphipathic helical peptides: Nucleation model of defect formationBiophysical Journal.  81:949-959. 2001
2000 Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1Journal of Lipid Research.  41:1481-1494. 2000
2000 Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3Journal of Lipid Research.  41:1495-1508. 2000
2000 Binding and cross-linking studies show that scavenger receptor BI interacts with multiple sites in apolipoprotein A-I and identify the class A amphipathic α-helix as a recognition motifJournal of Biological Chemistry.  275:18897-18904. 2000
2000 A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samplesJournal of Lipid Research.  41:1020-1026. 2000
2000 Structure and function of apolipoprotein A-I and high-density lipoproteinCurrent Opinion in Lipidology.  11:105-115. 2000
2000 The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblastsBiochemistry.  39:213-220. 2000
1999 Pre-beta-HDL stimulates placental lactogen release from human trophoblast cells.American Journal of Physiology.  276:E384-E389. 1999
1999 Pre-β-HDL stimulates placental lactogen release from human trophoblast cellsAJP - Endocrinology and Metabolism.  276. 1999
1999 Apolipoprotein-mediated plasma membrane microsolubilization: Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipidJournal of Biological Chemistry.  274:2021-2028. 1999
1999 Bioactivity of peptide analogs of the neutrophil chemoattractant, N- acetyl-proline-glycine-prolineInvestigative Ophthalmology & Visual Science.  40:2427-2429. 1999
1998 The lipid-free structure of apolipoprotein A-I: Effects of amino- terminal deletionsBiochemistry.  37:11714-11725. 1998
1998 Studies of synthetic peptides of human apolipoprotein A-I containing tandem amphipathic α-helixesBiochemistry.  37:10313-10324. 1998
1998 Studies of kinetics and equilibrium membrane binding of class A and class L model amphipathic peptidesBBA - Biomembranes.  1368:343-354. 1998
1997 Effect of vesicle size on their interaction with class A amphipathic helical peptidesJournal of Lipid Research.  38:2147-2154. 1997
1997 Interaction of class A amphipathic helical peptides with phospholipid unilamellar vesiclesJournal of Lipid Research.  38:2134-2146. 1997
1997 Role of lipids in the permeabilization of membranes by class L amphipathic helical peptidesBiochemistry.  36:9237-9245. 1997
1997 Truncation of the amine terminus of human apolipoprotein A-I substantially alters only the lipid-free conformationBiochemistry.  36:288-300. 1997
1996 Human placental tissue expresses a novel 22.7 kDa apolipoprotein A-I-like proteinBiochemistry.  35:7580-7585. 1996
1996 Probing structure and function of VLDL by synthetic amphipathic helical peptidesJournal of Lipid Research.  37:1099-1112. 1996
1996 Chromatographic methods for quantitation of apolipoprotein A-IMethods in Enzymology.  263:267-282. 1996
1996 Only the two end helixes of eight tandem amphipathic helical domains of human Apo A-I have significant lipid affinity: Implications for HDL assemblyArteriosclerosis, Thrombosis, and Vascular Biology.  16:328-338. 1996
1995 Molecular Basis for Prokaryotic Specificity of Magainin-Induced LysisBiochemistry.  34:4393-4401. 1995
1995 Structural models of human apolipoprotein A-IBBA - Lipids and Lipid Metabolism.  1256:103-129. 1995
1995 Effect of the arrangement of tandem repeating units of class A amphipathic α-helixes on lipid interactionJournal of Biological Chemistry.  270:1602-1611. 1995
1995 Effect of the cholesterol content of reconstituted LpA-I on lecithin:cholesterol acyltransferase activityJournal of Biological Chemistry.  270:5151-5157. 1995
1995 Efflux of Cellular Cholesterol and Phospholipid to Lipid-Free Apolipoproteins and Class A Amphipathic PeptidesBiochemistry.  34:7955-7965. 1995
1995 Localization of a Domain in Apolipoprotein E with both Cytostatic and Cytotoxic ActivityBiochemistry.  34:11142-11151. 1995
1995 Mechanisms for the modulation of membrane bilayer properties by amphipathic helical peptidesBiopolymers.  37:319-338. 1995
1995 Microenvironments of Basic Amino Acids in Amphipathic a-Helices Bound to Phospholipid: 13C NMR Studies Using Selectively Labeled PeptidesBiochemistry.  34:9219-9226. 1995
1994 Binding of apolipoprotein A-I model peptides to lipid bilayers. Measurement of binding isotherms and peptide-lipid headgroup interactionsJournal of Biological Chemistry.  269:23904-23910. 1994
1994 The influence of apolipoprotein structure on the efflux of cellular free cholesterol to high density lipoproteinJournal of Biological Chemistry.  269:22975-22982. 1994
1994 ApoB-100 has a pentapartite structure composed of three amphipathic α-helical domains alternating with two amphipathic β-strand domains: Detection by the computer program LOCATEArteriosclerosis, Thrombosis, and Vascular Biology.  14:1674-1685. 1994
1994 HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activityArteriosclerosis, Thrombosis, and Vascular Biology.  14:1775-1783. 1994
1994 Interactions of synthetic peptide analogs of the class A amphipathic helix with lipids. Evidence for the snorkel hypothesisJournal of Biological Chemistry.  269:7185-7191. 1994
1994 Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally similar to surface remnants of triglyceride- rich lipoproteinsArteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association.  14:622-635. 1994
1994 Mixing rates can markedly affect the kinetics of peptide-induced leakage from liposomesBiochemistry and Molecular Biology International.  33:1073-1079. 1994
1994 Pathogenesis of atherosclerosisCurrent Opinion in Cardiology.  9:404-410. 1994
1994 Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterolJournal of Clinical Investigation.  94:1698-1705. 1994
1994 The amphipathic α helix: A multifunctional structural motif in plasma apolipoproteinsAdvances in Protein Chemistry.  45:303-369. 1994
1993 Cytosolic domain of the human immunodeficiency virus envelope glycoproteins binds to calmodulin and inhibits calmodulin-regulated proteinsJournal of Biological Chemistry.  268:22895-22899. 1993
1993 An insulin receptor peptide (1135-1156) stimulates guanosine 5'[γ-thio]triphosphate binding to the 67 kDa G-protein associated with the insulin receptorBiochemical Journal.  294:19-24. 1993
1993 Effect of end group blockage on the properties of a class A amphipathic helical peptideProteins.  15:349-359. 1993
1993 Reciprocal effects of apolipoprotein and lytic peptide analogs on membranes. Cross-sectional molecular shapes of amphipathic α helixes control membrane stabilityJournal of Biological Chemistry.  268:22112-22118. 1993
1993 Solution structure of the v3 loop of a thailand hiv isolateJournal of Biomolecular Structure and Dynamics.  11:345-366. 1993
1992 Computer programs to identify and classify amphipathic α helical domainsJournal of Lipid Research.  33:287-296. 1992
1992 Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoproteinJournal of Biological Chemistry.  267:7121-7127. 1992
1992 The amphipathic helix in the exchangeable apolipoproteins: A review of secondary structure and functionJournal of Lipid Research.  33:141-166. 1992
1992 Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats: Correlation with physical propertiesArteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association.  12:886-894. 1992
1991 Apolipoprotein A-I decreases neutrophil degranulation and superoxide productionJournal of Lipid Research.  32:1911-1918. 1991
1991 Role of amphipathic helixes in HDL structure/functionAdvances in human genetics.  285:131-140. 1991
1991 Erratum: Amphipathic helix motif: Classes and properties (Proteins (1990) 8 (103-117))Proteins.  9:79. 1991
1991 Inhibition of virus‐induced cell fusion by apolipoprotein A‐I and its amphipathic peptide analogsJournal of Cellular Biochemistry.  45:224-237. 1991
1990 Thermodynamics of the binding of human apolipoprotein A-I to dimyristoylphosphatidylglycerolJournal of Biological Chemistry.  265:20829-20832. 1990
1990 Nuclear magnetic resonance investigation of the interaction with phospholipid of an amphipathic α-helix-forming peptide of the apolipoprotein classJournal of Biological Chemistry.  265:12217-12223. 1990
1990 Interactions of Serum Proteins with Small Unilamellar Liposomes Composed of Dioleoylphosphatidylethanolamine and Oleic Acid: High-Density Lipoprotein, Apolipoprotein A1, and Amphipathic Peptides Stabilize LiposomesBiochemistry.  29:3637-3643. 1990
1990 Amphipathic helix motif: Classes and propertiesProteins.  8:103-117. 1990
1990 Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogsVirology.  176:48-57. 1990
1990 Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formationJournal of Clinical Investigation.  86:1142-1150. 1990
1990 Use of synthetic peptide analogues to localize lecithin:cholesterol acyltransferase activating domain in apolipoprotein A-IArteriosclerosis (Dallas, Tex.).  10:95-105. 1990
1989 Nucleotide sequence of the gene for a fibronectin-binding protein from Staphylococcus aureus: Use of this peptide sequence in the synthesis of biologically active peptidesProceedings of the National Academy of Sciences.  86:699-703. 1989
1989 Properties of lipid complexes with amphipathic helix-forming peptides. Role of distribution of peptide chargesJournal of Biological Chemistry.  264:4628-4635. 1989
1989 Synthetic amphipathic peptides resembling apolipoproteins stimulate the release of human placental lactogenJournal of Biological Chemistry.  264:9215-9219. 1989
1988 Effect of oxidation on the properties of apolipoproteins A-1 and A-IIJournal of Lipid Research.  29:309-318. 1988
1987 Inhibition of chondroitin and heparan sulfate biosynthesis in Chinese hamster ovary cell mutants defective in galactosyltransferase I.Journal of Biological Chemistry.  262:12189-12195. 1987
1987 Synthesis of 3-O-β-d-xylopyranosyl-l-serine (xylosylserine) and O-β-d-galactopyranosyl-(1-4)-O-β-d-xylopyranosyl-l-serine (galactosylxylosylserine) and use of the synthetic products for detection of galactosyltransferase I activity in rat liverGlycoconjugate Journal.  4:255-266. 1987
1987 Studies of synthetic peptide analogs of the amphipathic helix. Effect of charge distribution, hydrophobicity, and secondary structure on lipid association and lecithin:cholesterol acyltransferase activation.Journal of Biological Chemistry.  262:9389-9396. 1987
1987 Structural and biological studies on synthetic peptide analogues of a low-affinity calcium-binding site of skeletal troponin CBBA - Proteins and Proteomics.  911:221-230. 1987
1987 Characterization of high density lipoprotein subspecies: Structural studies by single vertical spin ultracentrifugation and immunoaffinity chromatographyJournal of Lipid Research.  28:913-929. 1987
1986 [36] Synthetic Peptide Analogs of ApolipoproteinsMethods in Enzymology.  128:627-647. 1986
1985 Studies of synthetic peptide analogs of the amphiphatic helix. Structure of complexes with dimyristoyl phosphatidylcholineJournal of Biological Chemistry.  260:10248-10255. 1985
1982 Resolution of α-methyl amino esters by chymotrypsinTetrahedron Letters.  23:3335-3336. 1982
1980 Use of immobilized carboxypeptidase Y (I-CPY) as a catalyst for deblocking in peptide synthesisBiochimie.  62:537-541. 1980
1979 Removal of Benzyl-Type Protecting Groups from Peptides by Catalytic Transfer Hydrogenation with Formic AcidJournal of Organic Chemistry.  44:3442-3444. 1979
1977 Transfer hydrogenation; a convenient method for removal of some commonly used protecting groups in peptide synthesisJournal of the Chemical Society, Perkin Transactions 1.  490-491. 1977


Year Title Altmetric
2002 Experimental and computational studies of the interactions of amphipathic peptides with lipid surfaces.  Ed. 52.  2002


Year Title Altmetric
2010 HDL mimetic peptides: Novel therapeutic strategies for the treatment of inflammatory vascular disease.  179-197. 2010
2008 HDL and Inflammation.  339-354. 2008

Education And Training

  • Doctor of Philosophy in Biochemistry, Bangalore University 1978
  • Full Name

  • Gattadahalli Anantharamaiah